KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Accounts Payables (2016 - 2025)

NovoCure's Accounts Payables history spans 12 years, with the latest figure at $122.2 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 16.32% year-over-year to $122.2 million; the TTM value through Dec 2025 reached $122.2 million, up 16.32%, while the annual FY2025 figure was $122.2 million, 16.32% up from the prior year.
  • Accounts Payables for Q4 2025 was $122.2 million at NovoCure, up from $118.9 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $122.2 million in Q4 2025 and bottomed at $52.7 million in Q1 2021.
  • The 5-year median for Accounts Payables is $83.4 million (2023), against an average of $85.1 million.
  • The largest annual shift saw Accounts Payables skyrocketed 47.47% in 2021 before it increased 3.29% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $72.6 million in 2021, then rose by 17.35% to $85.2 million in 2022, then grew by 10.79% to $94.4 million in 2023, then rose by 11.33% to $105.1 million in 2024, then rose by 16.32% to $122.2 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Accounts Payables are $122.2 million (Q4 2025), $118.9 million (Q3 2025), and $103.7 million (Q2 2025).